• Users Online: 339
  • Print this page
  • Email this page

Table of Contents
Year : 2019  |  Volume : 2  |  Issue : 2  |  Page : 40-45

Vedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment

1 Department of Internal Medicine, Baylor College of Medicine, Houston, TX, USA
2 Department of Gastroenterology, Hepatology and Nutrition, Houston, TX, USA
3 Department of Pathology and Lab Medicine, MD Anderson Cancer Center, Houston, TX, USA
4 Department of Nuclear Medicine, Division of Diagnostic Imaging, MD Anderson Cancer Center, Houston, TX, USA

Date of Web Publication10-Apr-2019

Correspondence Address:
Dr. Yinghong Wang
Department of Gastroenterology, Hepatology, and Nutrition, MD Anderson Cancer Center, Houston, TX
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/JIPO.JIPO_18_18

Get Permissions


Immune checkpoint inhibitors (ICIs) have emerged as a novel therapeutic class for various malignancies. Their immune upregulation promotes significant anti-tumor effect, but simultaneously, can also result in treatment-limiting immune-related adverse events (irAEs). The data on upper gastrointestinal (GI) tract irAEs are sparse. We herein describe a case of steroid-dependent upper GI toxicity with nivolumab (an anti-programmed death [PD] protein-1) that achieved clinical and histological remission with vedolizumab treatment (a GI tract targeted anti-integrin antibody). A 65-year-old male patient with progressive lung cancer was treated with nivolumab and following 16 cycles, developed severe nausea, vomiting, and epigastric abdominal cramps requiring five hospitalizations. His initial esophagogastroduodenoscopy (EGD) showed active inflammation in both the stomach and duodenum. Nivolumab was discontinued, but despite treatment with multiple steroid courses, his symptoms always recurred during prednisone taper. Clinical remission was ultimately achieved with vedolizumab. His last EGD after five infusions of vedolizumab demonstrated resolution of inflammation. His lung cancer has since relapsed and the treatment plan was to resume nivolumab concurrently with vedolizumab. In conclusion, ICIs, such as nivolumab, have emerged as therapy for various malignancies. Their use can be associated with various irAEs including the upper GI adverse events which is uncommon. This case scenario showed that vedolizumab can provide a steroid-sparing therapeutic effect to achieve remission of upper GI irAEs even in cases where multiple steroid courses have failed.

Keywords: Adverse event, gastritis, gastrointestinal tract, immune checkpoint inhibitors, pancreatitis, vedolizumab

How to cite this article:
Tran CN, Abu-Sbeih H, Luo W, Lu Y, Wang Y. Vedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment. J Immunother Precis Oncol 2019;2:40-5

How to cite this URL:
Tran CN, Abu-Sbeih H, Luo W, Lu Y, Wang Y. Vedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment. J Immunother Precis Oncol [serial online] 2019 [cited 2020 Feb 28];2:40-5. Available from: http://www.jipoonline.org/text.asp?2019/2/2/40/249991

  Introduction Top

Immune checkpoint inhibitors (ICIs) have emerged as a novel therapeutic class for a wide variety of malignancies with demonstrated high effectiveness. Thus far, three sub-classes have been developed targeting cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), programmed death receptor-1 (PD-1), and PD-ligand 1 (PD-L1).[1],[2] Nivolumab is a human monoclonal IgG4 antibody that targets PD-1 and blocks its inhibitory effect on T-cell activity. This interaction releases the “brake” on the immune system imposed by PD-1 with the resultant significant anti-tumor effect, but simultaneously, can also induce toxicities from the nonspecific immunologic activation. The reported toxicities of PD-1 inhibitors include dermatologic, gastrointestinal (GI), hepatic, endocrine, and pulmonary immune-related adverse events (irAEs).[1],[2],[3],[4] Notably, among the GI irAEs associated with PD-1 inhibitors, upper GI tract adverse events (defined as nausea and vomiting and/or active inflammation in the stomach and duodenum) are less frequently reported than lower GI tract adverse events (defined as diarrhea and/or inflammation of the colon and distal ileum).[2],[5],[6] We herein describe a case of nivolumab-induced severe steroid-refractory upper GI irAE that was treated successfully with vedolizumab and achieved clinical and histological remission.

  Case Report Top

History of present illness

A 65-year-old male patient with metastatic nonsmall-cell lung cancer presented with nausea, vomiting, epigastric pain, decreased appetite, and 12-pound weight loss after 16 infusions of nivolumab therapy.

The patient had a prior medical history of emphysema, essential hypertension, hyperlipidemia, gastroesophageal reflux disease, and prostate cancer treated with leuprolide hormonal injection therapy. His surgical history was significant for prior cholecystectomy and appendectomy. He is a current smoker with 30 pack-year of smoking. Family history was significant only for his father who had stomach cancer.

The previous treatment of his lung cancer involved chemotherapy with pemetrexed and carboplatin at the time of diagnosis in 2013, followed by concurrent paclitaxel, carboplatin, and radiation therapy. He was found to have left upper lobe lung progression with new retroperitoneal lymph nodes and a solitary brain lesion in 2015 and underwent stereotactic radiation therapy with additional pemetrexed and carboplatin. In 2017, he was found to have progressive disease involving retroperitoneal lymphadenopathy, several small brain lesions, and possible liver metastases. Thereafter, nivolumab (at 3 mg/kg) was initiated.

Following the 13th cycle of nivolumab, he complained of the short duration of nausea and abdominal cramping that he attributed to food intolerance. At that time, a whole-body positron-emission tomography/computed tomography (PET/CT) showed no evidence of progressive malignancy but did show diffuse uptake in the stomach compatible with physiologic or inflammatory reaction. He received additional three cycles, and then developed a poor appetite, vomiting twice weekly, diarrhea, and a 12-pound weight loss. The patient received a total of 16 cycles of nivolumab until hisfirst hospitalization for progression of his upper GI symptoms of intractable nausea and vomiting associated with hypotension and epigastric pain. He denied any fever or sick contacts. His nivolumab treatment was discontinued due to the concern of GI toxicity.

On physical examination, he had a temperature of 36.7°C, the pulse of 99 beats/min, blood pressure of 98/69 mmHg, respiratory rate of 18/min, and normal oxygenation on ambient air. He appeared listless and cachectic. The abdomen was soft, nondistended, and tender at both lower quadrants. A CT of the abdomen and pelvis showed enhancement of the gastric mucosa suggestive of gastritis. An esophagogastroduodenoscopy (EGD) revealed a normal esophagus and an erythematous mucosa in the gastric body, antrum, and duodenal bulb; biopsies revealed chronic active gastritis and active duodenitis suggestive of nivolumab therapy-induced gastroenteritis [Figure 1]a and [Figure 1]b. Testing for Helicobacter pylori, Cytomegalovirus, and adenovirus was negative. His nausea, vomiting, and epigastric pain improved with empiric antibiotics, ondansetron, prochlorperazine, and pantoprazole, and he was discharged following 4 days hospitalization. After 10 days of discharge, he was hospitalized a second time for recurrent symptoms. Subsequently, 20 days later, he was hospitalized a third time for similar symptoms of nausea, vomiting, and epigastric pain. Two serial CT scans in the second and third hospital admissions showed new findings of mild edematous changes in the distal pancreatic body and tail with mild peripancreatic fat stranding suggesting early signs of uncomplicated pancreatitis, and unchanged gastric mucosal enhancement suggestive of gastritis. There was a new grade 3 elevation of serum lipase since the second admission with a peak of 784 U/L.[7] He was managed as acute pancreatitis with pain control and aggressive intravenous fluid during the second admission; however, he returned within 3 weeks with the same presentation, and this led to his third admission. Intravenous methylprednisolone was started (0.5 mg/kg daily twice daily) for potential ICI-induced gastritis and pancreatitis with immediate symptomatic improvement. After 3 days, he was transitioned to oral budesonide (9 mg daily open capsule) and was discharged following 4 days hospitalization.
Figure 1: Pathology of the stomach and duodenum pre-vedolizumab. (a) Pathology findings of the stomach pre-vedolizumab treatment. Moderately active chronic gastritis with abundant neutrophils in the epithelium. (b) Pathology findings of the duodenum pre-vedolizumab treatment. Active duodenitis with epithelial damage and crypt abscess.

Click here to view

Five days following discharge, he reported a recurrence of his nausea and vomiting despite budesonide treatment. Therefore, he was switched to prednisone (50 mg daily) for 2 weeks with a taper plan. However, his upper GI symptoms recurred when the prednisone was tapered down to 10 mg/day around the 6th week, which lead to the fourth hospitalization. A third CT showed submucosal edema of the proximal duodenum, enhancement of the small bowel mucosa with wall thickening, and decreased gastric wall thickening; features still suggestive of gastroenteritis. Repeated blood lipase level was normal. Intravenous methylprednisolone (40 mg every 8 h) was restarted for steroid-dependent gastroenteritis. He had immediate symptomatic improvement and was discharged following 2 days hospitalization with prednisone 60 mg daily on discharge.

Three days following discharge, he was readmitted a fifth time with a recurrence of intractable nausea, vomiting associated with epigastric pain, and new odynophagia. New oral thrush was confirmed, and odynophagia was treated with fluconazole. Intravenous methylprednisolone 60 mg every 12 h was restarted instead of oral prednisone. His nausea, vomiting, and epigastric pain rapidly improved, and he was switched to prednisone 40 mg daily after 4 days with a taper plan. Four days after the initiation of oral prednisone, he developed recurrence of abdominal pain and new-onset grade 1 diarrhea (2–3 loose BMs/day).[7] Examination was significant for hypotension with a blood pressure of 82/50 mmHg, tachycardia with a heart rate of 106, and minimal diffuse abdominal tenderness. Clostridium difficile testing showed positive DNA polymerase chain reaction and toxin (although toxin was negative 10 days prior). GI enteric pathogen testing was negative. He was treated with oral vancomycin intermittently for total 16 days. He remained on oral prednisone during this time. He recovered well with vancomycin and prednisone and was discharged following a 23 days hospitalization. A repeat EGD showed similar findings to the previous examination and pathology showed persistent active gastric and duodenal inflammation.

Vedolizumab initiation

Given the frequent requirement for high dose steroid treatment, candida and C. difficile infections, and hospital admissions for refractory upper GI irAEs, he was deemed to be a good candidate for a steroid-sparing agent. Approximately 1 month following discharge from his fifth hospitalization, vedolizumab infusion (300 mg) was initiated, and prednisone was tapered off within 1 week. He has remained symptom-free since then while maintaining a regular vedolizumab infusion schedule for the past 7 months. Repeat EGD after three doses of vedolizumab treatment still revealed mild gross inflammation and persistent histologic inflammation. His most recent EGD with biopsy, after five infusions of vedolizumab, confirmed a complete histologic resolution of active inflammation [Figure 2]a and [Figure 2]b. The clinical and treatment courses of this case are summarized in [Figure 3]. Unfortunately, the most recent restaging studies showed new hilar lymphadenopathy concerning for malignancy and increase in the size of right upper lobe metastasis. Given his history of refractory GI toxicity with nivolumab and effective control of the irAEs following vedolizumab treatment, the plan is to resume nivolumab with concurrent vedolizumab treatment. The serial PET/CT scan images of his upper GI toxicities are illustrated in [Figure 4].
Figure 2: Pathology of stomach and duodenum post 5 doses of vedolizumab. (a) Pathology findings of the stomach post-vedolizumab treatment. Reactive/chemical gastropathy without active inflammation. (b) Pathology findings of the duodenum post-vedolizumab treatment. Normal duodenal mucosa with no inflammation.

Click here to view
Figure 3: Severity of nivolumab-induced upper gastrointestinal toxicity. Grade of vomiting, and lipase elevation were assessed by common terminology criteria for adverse events version 5. Events of hospital admissions (orange squares) and vedolizumab infusions (purple triangles) are included with relation to symptom and steroid dose.

Click here to view
Figure 4: Fludeoxyglucose positron emission tomography/computed tomography images of the abdomen pre-vedolizumab (a-f). Post 3 doses of vedolizumab (g-i). Images of a, d, g are positron emission tomography, images of b, e, h are computed tomography, images of c, f, i are fused positron emission tomography/computed tomography. (a-c) Showing diffuse increased fludeoxyglucose uptake in the stomach with associated wall thickening, suggestive of gastritis (arrows). (d-f) Showing diffuse increased fludeoxyglucose update in the small bowel loops with associated wall thickening, suggestive of enteritis (arrows). (g-i) showing resolved abnormal fludeoxyglucose uptake and wall thickening in the stomach (short arrows) and small bowel loops (long arrows), suggestive of resolved gastritis and enteritis.

Click here to view

  Discussion Top

ICIs, including CTLA-4, PD-1, and PD-L1 have emerged as an effective treatment for a variety of advanced malignancies with manageable toxicities. ICI-induced adverse events can involve any organ system, of which the dermatologic, GI, hepatic, and endocrine systems are most commonly affected.[1],[2],[3],[4] GI irAEs are common and can lead to interruption of ICI treatment or even discontinuation.[3],[8],[9],[10] Most studies evaluating GI irAEs have discussed the adverse effects of the lower GI tract involving colitis and diarrhea.[2],[3],[8],[9],[10] A few case studies have reported upper GI tract injury involving esophagitis, gastritis, and duodenitis. Collins et al . and Gonzalez et al . reported that endoscopic inflammation of the upper GI tract was evident in 68% of the 25 patients who underwent EGD evaluation for GI symptoms.[11],[12]

When evaluating for possible upper GI symptoms, the differential can be broad; therefore, a thorough investigation is necessary to delineate other conditions, which may be contributing factors or the primary cause of the symptomatic presentation. For this patient, to determine the cause of his symptoms, diagnostic laboratory tests, microbiologic testing, numerous imaging studies, and endoscopic and histologic evaluation were utilized. Specifically, he underwent evaluation for GI infection, electrolyte disturbance, mechanical obstruction, and malignant progression as potential etiologies for his symptoms. After the exclusion of other competing etiologies for his upper GI symptoms, he was found to have pancreatitis on the basis of diagnostic laboratory and imaging studies. Similarly, he was diagnosed with immune-mediated gastroenteritis on the basis of diagnostic imaging and endoscopic evaluation with histologic confirmation. Hence, it is imperative to perform a thorough diagnostic evaluation to determine the cause of upper GI symptoms to guide an appropriate management plan.

In addition, upper GI symptoms of nausea, vomiting, and epigastric pain are nonspecific, and the current literature has focused on diarrhea and colitis with few studies discussing upper GI symptoms and the associated endoscopic and histologic findings.[2],[3],[8],[9],[10],[11],[12],[13] Collins et al . reported that in a study of 20 patients with GI irAEs, most had diarrhea (90%) followed by abdominal pain (70%) and nausea and vomiting (55%). A total of 19/20 (95%) received EGD with 13/19 (68%) showing abnormalities; however, in the clinical subgroups, only 4/20 (20%) had upper GI tract inflammation, 15/20 (75%) had colitis, and 1/20 (5%) had pseudo-obstruction. Of the patients with colitis, 14/20 received EGD and 9/14 (64%) had upper GI tract abnormalities.[11] Therefore, the lack of upper GI irAE reporting is possibly due to several reasons.[1] The concomitant occurrence of upper and lower GI tract injury where it is considered a lower GI irAE due to the predominance of lower GI symptoms,[2] the lesser severity of many upper GI symptoms (including nausea, anorexia, and dysphagia) relative to lower GI symptoms, and[3] the infrequent use of EGD to investigate GI irAE.[2],[10],[11],[12],[13] Among the case studies reporting upper GI irAEs, findings on EGD are quite variable ranging from normal-to-severe inflammation with gastric mucosal ulcerations and even necrotizing gastritis.[11],[12],[13] Histologic features of gastric and duodenal inflammation include lymphoplasmacytic lamina propria expansion, abscess formation, abundant intra-epithelial neutrophils and lymphocytes, and specific to the duodenum, villous blunting.[11],[12],[13]

The occurrence of immune-related pancreatitis in the setting of ICI therapy is quite rare. Michot et al . reported that among a cohort of 909 patients treated with anti-PD-1 or anti-PD-L1 therapy, only 0.3% had immune-related pancreatitis evident by imaging studies.[14] Furthermore, the clinical presentations and outcomes of ICI-induced pancreatitis are only described in a few case reports, and the management of immune-related pancreatitis is not well established.[14],[15],[16],[17] The current recommendation of methylprednisolone 1–2 mg/kg/day or equivalent is based on few case reports.[15] Thus, further studies investigating the features of ICI-induced pancreatitis are warranted to develop a systematic approach to the diagnosis and treatment of ICI-induced pancreatitis.

The treatment of upper GI irAEs is not well established. Currently, given that irAEs are mediated by general immunologic activation, the current consensus guidelines for the treatment of GI irAEs recommend 1–2 mg/kg/day methylprednisolone or equivalent for grade 2 or higher adverse events.[3],[8],[10] However, corticosteroid treatment induces systemic immunosuppression, which is associated with significant morbidity. In this patient, as a consequence of corticosteroid treatment, he suffered from candida esophagitis and C. difficile infection with associated prolonged hospitalizations. Furthermore, GI irAEs, like in this case, might be steroid-refractory or steroid-dependent, which necessitate a long course of steroids, causing increased burden on the patient.[3],[8],[10] There is also debate on the potential undesirable impact of systemic immunosuppression on the anti-tumor effect of ICI treatment, although this has not been proven in small studies.[18],[19],[20],[21],[22],[23] Altogether, the potential adverse effects associated with steroids highlight the importance of an effective steroid-sparing therapy that is safe without inducing systemic immunosuppression. Particularly in steroid refractory diseases, the early introduction of such agent is of significance to avoid unwanted morbidity.

Vedolizumab, a human monoclonal IgG1 antibody against α4 β7 integrin, promotes a gut-specific immunosuppression with a gradual onset of therapeutic effect. It is approved for the treatment of inflammatory bowel diseases, Crohn's and Ulcerative Colitis. Recently, vedolizumab has been described as a treatment for immune-related enterocolitis in a case series and in a case report, as a treatment for immune-related enteritis.[22],[23] In this case study, vedolizumab was associated with symptomatic resolution within 2 weeks and eventually, complete histologic remission. The gut-specific activity of vedolizumab could be promising for its use in conjunction with cancer immunotherapy since it does not alter the extra-intestinal immunity.[22],[23] The other confounding factor in the favorable outcome of GI irAE, in this case, is the potential waning effect of immunotherapy supported by the evidence of recurrent cancer.

To date, this is thefirst case study to describe the potential efficacy of vedolizumab in the treatment of upper GI irAEs. However, the significant limitation attached to the nature of any case study precludes any meaningful recommendations regarding the effectiveness of vedolizumab for the treatment of upper GI irAEs. Hence, large-scale studies are needed to investigate further the efficacy and safety of vedolizumab in the treatment of upper GI irAEs.

  Conclusion Top

Gastroenteritis and pancreatitis are uncommon adverse events with ICI treatment. The nonspecific presentation of both and the wide differential of etiologies could lead to the misdiagnosis of these entities. Therefore, a thorough diagnostic evaluation with a high level of awareness of the features of ICI toxicities is crucial to attain the right diagnosis and provide the appropriate treatment. Although steroids arefirst-line therapy with proven effectiveness in most cases of irAEs, steroid-refractory cases can lead to significant morbidity if appropriate treatment is not provided in a timely manner. We reported thefirst case of steroid-refractory upper GI injury concurrent with pancreatitis secondary to nivolumab treatment that was successfully treated with vedolizumab achieving clinical and histologic remission at 7 months follow-up. With the increasing number of ICIs in the current clinical practice, it is reasonably anticipated that the incidence of all irAEs will rise. Therefore, it is imperative that all clinicians be made aware of their potential adverse effects to prompt rapid diagnosis and treatment.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

The authors disclosed no funding related to this article.

Conflicts of interest

The authors disclosed no conflicts of interest related to this article.

  References Top

Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015;33:1974-82.  Back to cited text no. 1
Abdel-Rahman O, ElHalawani H, Fouad M. Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: A meta-analysis. Immunotherapy 2015;7:1213-27.  Back to cited text no. 2
Eigentler TK, Hassel JC, Berking C, et al . Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 2016;45:7-18.  Back to cited text no. 3
Nishijima TF, Shachar SS, Nyrop KA, et al. Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: A meta-analysis. Oncologist 2017;22:470-9.  Back to cited text no. 4
Robert C, Long GV, Brady B, et al . Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-30.  Back to cited text no. 5
Weber JS, D'Angelo SP, Minor D, et al . Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375-84.  Back to cited text no. 6
National Cancer Institute. Common Terminology Criteria for Adverse Events. Version 5.0. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2017. Available from: http://www.evs.nci.nih.gov/ftp1/CTCAE/About.html. [Accessed Jan 03, 2019].  Back to cited text no. 7
Puzanov I, Diab A, Abdallah K, et al . Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017;5:95.  Back to cited text no. 8
Hofmann L, Forschner A, Loquai C, et al . Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 2016;60:190-209.  Back to cited text no. 9
Haanen JB, Carbonnel F, Robert C, et al . Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28:iv119-iv142.  Back to cited text no. 10
Collins M, Michot JM, Danlos FX, et al . Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol 2017;28:2860-5.  Back to cited text no. 11
Gonzalez RS, Salaria SN, Bohannon CD, et al . PD-1 inhibitor gastroenterocolitis: Case series and appraisal of 'immunomodulatory gastroenterocolitis'. Histopathology 2017;70:558-67.  Back to cited text no. 12
Shi Y, Lin P, Ho EY, et al. Nivolumab-associated nausea and vomiting as an immune adverse event. Eur J Cancer 2017;84:367-9.  Back to cited text no. 13
Michot JM, Ragou P, Carbonnel F, et al . Significance of immune-related lipase increase induced by antiprogrammed death-1 or death ligand-1 antibodies: A brief communication. J Immunother 2018;41:84-5.  Back to cited text no. 14
Ikeuchi K, Okuma Y, Tabata T. Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report. Lung Cancer 2016;99:148-50.  Back to cited text no. 15
Friedman CF, Clark V, Raikhel AV, et al . Thinking critically about classifying adverse events: Incidence of pancreatitis in patients treated with nivolumab+ipilimumab. J Natl Cancer Inst 2017;109(4).  Back to cited text no. 16
Capurso G, Archibugi L, Tessieri L, et al . Focal immune-related pancreatitis occurring after treatment with programmed cell death 1 inhibitors: A distinct form of autoimmune pancreatitis? Eur J Cancer 2018;95:123-6.  Back to cited text no. 17
De Felice KM, Gupta A, Rakshit S, et al . Ipilimumab-induced colitis in patients with metastatic melanoma. Melanoma Res 2015;25:321-7.  Back to cited text no. 18
Arriola E, Wheater M, Karydis I, et al. Infliximab for IPILIMUMAB-related colitis-letter. Clin Cancer Res 2015;21:5642-3.  Back to cited text no. 19
Attia P, Phan GQ, Maker AV, et al . Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23:6043-53.  Back to cited text no. 20
Horvat TZ, Adel NG, Dang TO, et al . Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial Sloan Kettering cancer center. J Clin Oncol 2015;33:3193-8.  Back to cited text no. 21
Bergqvist V, Hertervig E, Gedeon P, et al . Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother 2017;66:581-92.  Back to cited text no. 22
Diana P, Mankongpaisarnrung C, Atkins MB, et al. Emerging role of vedolizumab in managing refractory immune checkpoint inhibitor-induced enteritis. ACG Case Rep J 2018;5:e17.  Back to cited text no. 23


  [Figure 1], [Figure 2], [Figure 3], [Figure 4]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
  Case Report
   Article Figures

 Article Access Statistics
    PDF Downloaded194    
    Comments [Add]    

Recommend this journal